Search for new drugs to reduce TBI severity continues

Share

Citicoline, an endogenous compound found in neural tissue, has not proven to have the neuroprotective qualities as was hoped prior to the conclusion of the most recent study involving the treatment of individuals with recent TBI. When compared to the placebo-treated group there was little difference from the Citicoline-treated cohort. These studies remain so vital to the need to reduce the neurological consequences of traumatic brain injuries and improve the outcomes available to people with TBI.

We look forward to the development of better methods to reduce injury severity, promote recovery and allow people with brain injuries to experience lower levels of disabilities. Each study offers new hope and the anticipation that disability from brain injury can be reduced.

Click here to read a summary of the study:

http://www.news-medical.net/news/20121122/Citicoline-not-superior-to-placebo-in-treating-traumatic-brain-injury.aspx

Tag lines: Severe Brain Injury Outcomes, TBI Rehabilitation, Citicoline and TBI, neuroprotective drugs

About Rolf Gainer Ph.D.

Dr. Rolf Gainer is the founder of the Neurologic Rehabilitation Institute at Brookhaven Hospital in Tulsa, Oklahoma as well as the Neurological Rehabilitation Institute of Ontario, in Toronto, Canada. Dr. Gainer is a psychologist with more than twenty-five years of experience in the treatment and rehabilitation of individuals with brain injuries and a dual diagnosis. Dr. Gainer has designed and operated innovative rehabilitation programs in the United States and Canada for individuals who have been regarded as difficult to serve. He is currently involved in conducting two outcome studies related to the long-term issues faced by individuals with brain injuries and a dual diagnosis. He has presented papers throughout the United States and Canada in many professional conferences and educational forums.
No comments yet.

Leave a Reply